NHS trial of blood test offers 'genuine hope' for people with some cancers
Grail said the test showed high specificity and positive predictive value, but the trial did not reduce stage III-IV cancers over 3 years.
- On Saturday, Grail presented Galleri trial results at the American Society of Clinical Oncology annual meeting in Chicago, confirming the blood test missed its primary endpoint of reducing late-stage cancer diagnoses.
- The NHS-Galleri trial enrolled 142,942 asymptomatic adults aged 50 to 77 and aimed for a statistically significant reduction in stage III-IV cancers over 3 years; this ambitious primary goal was not met.
- Despite missing the primary target, secondary findings showed 14% fewer cancers diagnosed at stage 4 and 19% more found at stages 1, 2 and 3, with 25% fewer patients diagnosed in emergency settings, Grail reported.
- Professor Richard Houlston of the Institute of Cancer Research, London, argued researchers presented findings "far more positively than the overall results justify," while concerns persist about strain on the NHS 80% Faster Diagnosis Standard.
- The upcoming Reach study, which will trial Galleri on about 50,000 US patients, will provide critical information to weigh the benefits and risks of early detection blood tests, according to experts.
21 Articles
21 Articles
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its lar
PR Newswire
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round...
Grail’s cancer blood test still isn’t ready for widespread use, experts say
The NHS-Galleri trial was the first randomized controlled study conducted on a cancer detection blood test, but the findings suggest Grail's tests are not yet be ready for broad and regular cancer screening use, experts not involved with the study said.
Why was the multi-cancer test failing?
NHS trial finds Galleri blood test didn’t meet its main goal A trial of the multi cancer blood test Galleri—studied in 142,000 NHS patients—failed to meet its main aim. Results presented at an oncology conference in Chicago found that the test did not reduce late stage cancer diagnoses. Galleri is…
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
